Biotech News

Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously

Phathom Pharmaceuticals (PHAT)Phathom PharmaceuticalsCompany update

Heartburn two or more times a week may be a sign of gastroesophageal reflux disease (GERD), which affects an estimated 65 million Americans A Media Snippet accompanying this announcement is available by clicking on this link. FLORHAM PARK, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Phathom

Related news

Phathom Pharmaceuticals

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive...

Recent company news

Stock data

Close
5.08 USD
Market cap
769.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States